An Study of Aripiprazole in the Treatment of Methamphetamine Dependence

A Multiple-Center, Randomized, Double-Blind Study of Aripiprazole for Treatment of Methamphetamine Dependence

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01813656

Enrollment

Registered

2013-03-19

Start date

2012-09-30

Completion date

2014-02-28

Last updated

2015-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methamphetamine Dependence

Keywords

Methamphetamine-Associated Psychosis, Aripiprazole

Brief summary

Methamphetamine substance use is common worldwide. No approved pharmacologic treatments for methamphetamine dependence exist. Aripiprazole are Second generation antipsychotics，but have different pharmacological effects of neurotransmitters.To determine whether mirtazapine would reduce methamphetamine use among mehtamphetamine addicts.

Detailed description

Methods:A Multiple-Center, Randomized, Double-Blind.

Interventions

DRUGAripiprazole

Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks

DRUGplacebo

placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

19 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV) criteria for Methamphetamine dependence. 2. Must sign a Information consent form. 3. Required to provide detailed address and phone number

Exclusion criteria

1. Serious organic disease. 2. Suicide ideation or hurt others. 3. Taking antipsychotic within two weeks before. 4. drug allergy to Risperidone or Aripiprazole. 5. pregnancy and breastfeeding women.

Design outcomes

Primary

Measure	Time frame	Description
abstinent time of Methamphetamine addict	up to 3 months	methamphetamine-positive urine test results,self-reports of substance use

Secondary

Measure	Time frame	Description
number of Participants with Adverse Events as a Measure of Safety and Tolerability	up to 3 months	use Abnormal Involuntary Movement Scale ,Simpson-Angus Scale and Barnes akathisia Scale

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026